PBI’s Founder Professor T.-C. Wu gave an opening speech by briefly reviewing PBI’s history and introducing our recent changes, including the hiring of Dr. M. Joe Ma as PBI’s new CEO in March of 2021.

This was followed by Dr. Ma’s presentaton of current status and future plans for PBI’s two pipeline products under development – PVX2 and PVX7.  Dr. Ma shared the exciting preliminary results of PVX2’s ongoing phase II clinical trial, and laid out our plans to complete phase II clinical trials of both products in the next 2-3 years. He clearly outlined the goal of IPO in Taiwan in 2024.  The budget of these plans was presented, and the details of this A round of fundraising were described.

Last, President Lily Wu gave an inspiring remark before the dinner was served.  Guests and Shareholders alike were excited by the presentation and interacted with PBI leaders freely.  The dinner concluded at around 09:30 PM.

The post PBI Shareholder Dinner Meeting in January 2022 appeared first on PapiVax Biotech, inc..

The post Vaccine World Asia Congress 2020 appeared first on PapiVax Biotech, inc..

The post Papivax Biotech Inc. participated in the 2019 Asia Biotechnology Conference Bio Asia-Taiwan appeared first on PapiVax Biotech, inc..

The precursor lesions of cervical cancer (HSIL) are effectively treated by ablative therapy such as cold knife conization or Loop Electrosurgical Excision Procedure (LEEP). However, this surgical procedure is associated with elevated rates of cervical incompetence and premature delivery of children, as well as recurrence. The precursor lesions of other anogenital cancers are less successfully treated by ablation with side effects of pain and genital disfigurement or fecal incontinence. There are no defined precursor lesions of oropharyngeal cancer to treat unfortunately.

With the development of routine cervical screening by Pap and/or molecular viral testing, large numbers of women are discovering that they carry a high risk HPV infection including HPV16 but do not yet need ablative therapy (i.e. they have a low grade lesion). Unfortunately, currently there is no medical treatment for these patients except for waiting and re-screening. Patients in this situation not only have a greatly increased potential to develop cervical cancer but also suffer significant psychological stress associated with a sexually transmitted infection. The condition also imposes risks for their sex partners or spread to other anogenital or oral sites, thereby creating significant social-psychological burden for the patients and their partners.

Currently there is not enough attention being paid to these important unmet needs.  PBI intends to address these unmet medical issues through the development of innovative therapeutic HPV vaccine technologies.

In addition, could you share with us 2 areas you are looking to optimize? (with respect to processes, partnerships etc.)
The operation strategy for PBI is to employ streamlined approach for their management and clinical development and to minimize physical infrastructure requirements. Thus, most of our resources are retained for the manufacturing of clinical grade vaccines as well as for early phase clinical testing. We have developed our own IP strategies through collaboration with and licensing from academic institutions. However, this virtual approach is only suitable for the early development and proof of concept through phase II. Thus, PBI is currently looking for strategic partners who can optimize subsequent clinical development towards licensure.

Do you have anything exciting coming up in the next year? What should the industry look out for from your organization?
Yes, we have an ongoing double-blind placebo-controlled phase II study in patients with persistent HPV16 infection and low grade cervical disease using PBI’s innovative therapeutic HPV vaccine technology. This is the only phase II clinical trial in this group of patients currently. So far, there is no treatment for this group of patients beyond waiting and re-screening. With the increased molecular HPV testing for the screening of HPV-associated pre-cancers, we expect to see significant number of such patients with persistent high risk HPV infections, particularly HPV16.  Thus, the successful outcome of our trial will serve as proof-of-concept for treatment of this group of patients to address their important unmet medical needs.

About Ms. Lily Wu
President Lily Wu is an experienced CEO with finance expertise. She has more than 20 years of leadership experience in finance and real estate enterprises. She was also one of the co-founders of Papivax Biotech Inc. (PBI). Ms. Wu was awarded a Master of Business Administration degree from the Executive Master’s Program of Business Administration: Advanced Management Program at Feng Chia University.

About PapiVax
PapiVax Biotech Inc. (PBI) is a Taiwan-based biopharmaceutical corporation that focuses on the development of novel therapeutic vaccines for human papillomavirus (HPV)-associated diseases.

The post Papivax Biotech Inc. Chairperson Lili Wu’s interview with Pharma Boardroom appeared first on PapiVax Biotech, inc..

The post Papivax Biotech Inc. participated in the TRANS International Biomedical Innovation Forum appeared first on PapiVax Biotech, inc..